Telomir Pharmaceuticals Inc. (TELO)
NASDAQ: TELOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TELO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $26.82M
- EPS (TTM)
- -$0.96
- Dividend yield
- None
- 52-week range
- 0.353 – 1.58
- Day range
- 0.3578 – 0.4371
- Volume / Avg
- 255.91K / 126.14K
- Beta
- —
- Shares outstanding
- 73.68M
52-week range
TELO stock today
On Nov 20, TELO ended the session at $0.364, shedding $0.0758 (17.24%), versus the S&P 500's 3.70% decline. Volume was 2.0x the average at 255.91K shares, a sign of unusually heavy trading. At this level, TELO sits near the bottom of its 52-week range of $0.353 to $1.58: 77.0% below the high, set on Oct 6, 2026 and 3.1% above the low.
TELO is down 72.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 71.6%. Telomir Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.96), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Telomir Pharmaceuticals
Company profileTelomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Erez Aminov
- Headquarters
- Miami, FL
- IPO year
- 2024
- Website
- telomirpharma.com
Financial highlights
Full financialsTelomir Pharmaceuticals reported a net loss of $10.4 million, compared with a loss of $16.5 million a year earlier. Diluted earnings per share came in at -$0.33.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Growth | — | — | — | — |
| Net income | $-10.41M | $-16.53M | $-13.07M | $-854.15K |
| EPS (diluted) | $-0.33 | $-0.56 | $0.48 | $-0.03 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$4.00+998.90%
- Strong buy 1
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.01 vs —
TELO news
All TELO newsTelomir Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NSRXNasus Pharma Ltd. | 2.29 | -10.20% | $26.82M | vs TELO |
| BCTXBriaCell Therapeutics Corp. | 3.06 | -3.32% | $26.72M | vs TELO |
| EDSAEdesa Biotech Inc. | 2.00 | -8.05% | $27.02M | vs TELO |
| PMNProMIS Neurosciences Inc. | 3.16 | -1.56% | $28.43M | vs TELO |
| AYTUAytu BioPharma Inc. | 2.66 | 0.00% | $28.91M | vs TELO |
| ATHEAlterity Therapeutics Limited ADR | 1.52 | -8.16% | $29.02M | vs TELO |
| RNTXRein Therapeutics Inc. | 0.3369 | -8.38% | $29.06M | vs TELO |
| NNVCNanoViricides Inc. | 1.14 | -2.56% | $29.13M | vs TELO |
Indexes, lists and sector
Telomir Pharmaceuticals stock FAQ
What is Telomir Pharmaceuticals's stock price today?
TELO last traded at $0.364 as of Nov 20, 4:00 PM EST, down 17.24% on the day. Prices are delayed at least 15 minutes.
Who is Telomir Pharmaceuticals's CEO?
Mr. Erez Aminov is the chief executive officer of Telomir Pharmaceuticals Inc..
What is the TELO 52-week high?
The 52-week high for TELO is $1.58 and the 52-week low is $0.353. The stock is currently 77.0% below its high.